260 completed, 153 active not recruiting, 141 recruiting, 117 terminated. 459 Phase 2, 251 Phase 1, 127 Phase 3, 11 Early Phase 1, 7 Not applicable.
Follow atezolizumab: new trials by email Literature Review of atezolizumab trials Research Report on atezolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-10-22 |
| A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients OTS-412, Hydroxyurea (HU), Atezolizumab - Treatment-Refractory Solid Tumors | Phase 1 | Not yet recruiting | Bionoxx Inc. | 24 | 2027-01-01 | 2026-08-26 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-19 | 2026-09-29 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 32 | 2026-10-06 | 2026-10-13 |
| Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab - Osteosarcoma, Pulmonary Recurrence of Osteosarcoma | Phase 1 | Recruiting | Emory University | 12 | 2026-10-01 | 2026-09-30 |
| Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma Folic Acid, Atezolizumab & Bevacizumab - Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 78 | 2026-10-01 | 2026-09-23 |
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
| Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Mark Bernard | 35 | 2026-09-09 | 2026-10-14 |
| Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tocilizumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | CHA University | 51 | 2026-09-01 | 2026-08-19 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer DSP-0390, Atezolizumab - Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2026-08-03 | 2026-08-04 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-08-18 |
| A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer BL-M14D1, Atezolizumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 36 | 2026-07-09 | 2026-08-25 |
| Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC Atezolizumab and Bevacizumab - Resectable Hepatocellular Carcinoma | Phase 2 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | 90 | 2026-06-02 | 2026-07-08 |
| Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Bindu R Potugari | 35 | 2026-05-14 | 2026-07-28 |
| Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma TACE-HAIC + Atezolizumab + Low-dose Bevacizumab - Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab | Not applicable | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-05-01 | 2026-04-22 |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy obrixtamig, atezolizumab, carboplatin - Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Boehringer Ingelheim | 670 | 2026-04-13 | 2026-10-20 |
| A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors YL201, Atezolizumab - Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 118 | 2026-03-31 | 2026-09-17 |
Showing 20 of 774. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (137) · Carcinoma, Hepatocellular (83) · Small Cell Lung Carcinoma (54) · Neoplasms (53) · Breast Neoplasms (50) · Lung Neoplasms (45) · Triple Negative Breast Neoplasms (41) · Colorectal Neoplasms (39) · Melanoma (38) · Carcinoma, Transitional Cell (37) · Urinary Bladder Neoplasms (33) · Neoplasm Metastasis (32) · Carcinoma, Renal Cell (30) · Ovarian Neoplasms (20) · Uterine Cervical Neoplasms (20)
Hoffmann-La Roche (161) · National Cancer Institute (NCI) (47) · Genentech, Inc. (28) · M.D. Anderson Cancer Center (25) · Memorial Sloan Kettering Cancer Center (8) · The Netherlands Cancer Institute (8) · Exelixis (6) · Gustave Roussy, Cancer Campus, Grand Paris (5) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (5) · Intergroupe Francophone de Cancerologie Thoracique (5) · Queen Mary University of London (5) · Samsung Medical Center (5) · Washington University School of Medicine (5) · Boehringer Ingelheim (4) · CHA University (4)
United States (459) · Spain (201) · France (161) · Italy (142) · South Korea (140) · Germany (139) · United Kingdom (127) · Australia (109) · Canada (102) · China (100) · Belgium (92) · Poland (92) · Taiwan (80) · Japan (71) · Netherlands (71)
Mariano Provencio, MD (4) · Marleen Kok, MD (3) · A P Chen (2) · Angelica Loskog, PhD (2) · Daniel Morgensztern, M.D. (2) · Daniel Morgensztern, MD (2) · David H Smith, MD (2) · Evan Osmundson, MD, PhD (2)
PMID 33241650, PMID 32450725, PMID 35511917, PMID 27939400, PMID 31542806, PMID 33476492, PMID 35623069, PMID 36310331, PMID 36795388, PMID 25428504, PMID 26952546, PMID 26970723, PMID 32115349, PMID 34409776, PMID 36428744, PMID 36940261, PMID 37146227, PMID 37185961, PMID 39532375, PMID 41144872, PMID 41449151, PMID 42214243, PMID 42526918, PMID 11224527, PMID 12091876, PMID 12118019, PMID 12538684, PMID 12586807, PMID 12648575, PMID 1355007, PMID 14529770, PMID 14639532, PMID 15030777, PMID 15169803, PMID 1569695, PMID 15761078, PMID 17340590, PMID 17684133, PMID 18676751, PMID 19097774, PMID 19219610, PMID 19687335, PMID 19826121, PMID 20620859, PMID 20697067, PMID 20850152, PMID 21205755, PMID 2144854, PMID 21537039, PMID 22065672
2017 (28), 2016 (26), 2023 (26), 2019 (20), 2014 (19), 2015 (16), 2018 (16), U10CA180868 (9), U10CA180888 (9), UM1CA186691 (7), 2025 (5), U10CA180821 (4), P30CA014089 (3), P30CA033572 (3), U10CA180820 (3)